Thiopurine
Thiopurine is an analogue of a purine wherein a C=O/C-OH group has been replaced by a C=S/C-SH group. These organosulfur compounds are bioactive in beneficial and complicating manner. They interfere with purine biosynthesis. Thiopurine drugs antimetabolites widely used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g., Crohn's disease, rheumatoid arthritis), and organ transplant recipients. Azathioprine is a prodrug. 6-Mercaptopurine is substrate for three enzyme]]s: thiopurine methyltransferase (to give 6-methylmercaptopurine), xanthine oxidase (to give 6-thiouric acid], and hypoxanthine phosphoribosyltransferase (to give 6-thioisonine 5'-monphosphate).[1] They are also substrates for nudix hydrolase 15 (NUDT15).[2]
Controversy
[edit | edit source]Litigation over patents covering diagnostic kits to monitor the dosing of these drugs led to a US Supreme Court case, Mayo Collaborative Services v. Prometheus Laboratories, Inc. that dramatically changed the nature of patent law in the United States.[3][4]
See also
[edit | edit source]- 6-Mercaptopurine (6-MP)
- 6-Thioguanine (6-TG)
- Azathioprine (AZA)
References
[edit | edit source]- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Supreme Court Decision. Mayo Collaborative Services v. Prometheus Laboratories, Inc., No. 10-1150, Slip Op. at 16. Decision
- ^ Gene Quinn, Killing Industry: The Supreme Court Blows Mayo v. Prometheus IP Watchdog (March 20, 2012).
External links
[edit | edit source]
